nystatin orifarm 100 000 iu/ml oraalisuspensio
orifarm generics a/s - nystatin - oraalisuspensio - 100 000 iu/ml - nystatiini
buranagel 50 mg/g geeli
orion corporation - ibuprofen - geeli - 50 mg/g - ibuprofeeni
clindamycin sanoswiss 150 mg kapseli, kova
sanoswiss uab - clindamycin hydrochloride - kapseli, kova - 150 mg - klindamysiini
clindamycin sanoswiss 300 mg kapseli, kova
sanoswiss uab - clindamycin hydrochloride - kapseli, kova - 300 mg - klindamysiini
xefal 500 mg kapseli, kova
antibiotice sa - cefalexin monohydrate - kapseli, kova - 500 mg - kefaleksiini
deflazacort vital pharma nordic 30 mg tabletti
vital pharma nordic aps - deflazacort - tabletti - 30 mg - deflatsakorti
deflazacort vital pharma nordic 6 mg tabletti
vital pharma nordic aps - deflazacort - tabletti - 6 mg - deflatsakorti
ambroxol ratiopharm 60 mg poretabletti
teva b.v. - ambroxol hydrochloride - poretabletti - 60 mg - ambroksoli
lacosamide accord
accord healthcare s.l.u. - lakosamidi - epilepsia - epilepsialääkkeet, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy• in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
lacosamide adroiq
extrovis eu ltd. - lakosamidi - epilepsia - epilepsialääkkeet, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.